Bring the potential of ROZLYTREK® to life

ROZLYTREK

offers convenient

once-daily,

oral dosing1

ROZLYTREK offers convenient once-daily, oral dosing1

  • The recommended dose for adults is 600 mg orally once-daily
  • ROZLYTREK can be taken with or without food

ROZLYTREK dosing

Dosing

Pills
Food
  • Adults: Recommended dose is 600 mg orally once-daily
  • Children > 6 months:

Table 1: Recommended dosing for paediatric patients > 6 months

*BSA categories and recommended dosing in Table 1 are based on closely matching exposures to a target dose of 300 mg/m2
**To enable dosing increments of 10 mg, capsules prepared as an oral suspension may be used. Refer to the Method of Administration section below and section 6.6. 

Paediatric patients > 1 month to ≤ 6 months of age
The recommended dose for paediatric patients > 1 month to ≤ 6 months of age is 250 mg/m2 BSA entrectinib once daily, using capsules prepared as an oral suspension. 

 
  • Available in 100 mg and 200 mg hard capsules and as 50 mg film-coated granules in sachet
  • Can be taken with or without food
    • No significant effect of food on bioavailability was observed

ROZLYTREK dosing modifications

 

Temporary interruption, dose reduction or discontinuation of treatment with ROZLYTREK may help manage adverse reactions1

 

Dose reduction

Table 2: Dose reduction schedule for adult and paediatric patients

*To enable dosing increments of 10 mg, capsules prepared as an oral suspension may be used. Refer to the Method of administration section below and section 6.6.
**Monday (100 mg), Tuesday (50 mg), Wednesday (100 mg), Thursday (50 mg), Friday (100 mg), Saturday (50 mg), and Sunday (100 mg).

Does Reduction for Specific Adverse Reactions

ROZLYTREK SmPC

Download the ROZLYTREK Summary of Product Characteristics

To read the full product information:

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for details on how to report adverse reactions.

Footnotes

ALT, alanine aminotransferase; AR, adverse reaction; AST, aspartate aminotransferase; BSA, body surface area; ms, millisecond; QT, time from the start of the Q wave to the end of the T wave; QTc, the corrected QT interval; SmPC, summary of product characteristics; ULN, upper limit of normal.

References

  1. ROZLYTREK Summary of Product Characteristics, 2025.